Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation
- 409 Downloads
Glioma is one of the lethal malignancies with poor prognosis. In addition, glioma stem cells (GSCs) have been considered as the crucial player that attributed to the tumorigenesis and drug resistance. In the current study, we investigated the therapeutic effect of hinokitiol, a natural bioactive compound of aromatic tropolone, on the characteristics of GSCs and the possible mechanism.
U87MG and T98G glioma cells were used to isolate GSCs. CD133 positivity and ALDH1 activity of GSCs following hinokitiol treatment were assessed by flow cytometry analysis. Secondary sphere formation, migration, invasion, and colony-forming assays were performed to examine the self-renewal capacity and oncogenicity in GCS after hinokitiol administration. The expression of Nrf2 was evaluated by RT-PCR and western blot analyses.
We demonstrated that hinokitiol effectively inhibited the CD133 positivity and ALDH1 activity along with the reduced self-renewal, migration, invasion, and colony formation properties of GSCs. In addition, hinokitiol repressed the gene and protein expression of Nrf2, which has been shown to be critical for those GSCs features. Furthermore, we showed that administration of exogenous Nrf2 counteracted the inhibitory effect of hinokitiol on self-renewal and invasiveness of GSCs.
These evidences suggest that treatment of hinokitiol significantly attenuates the hallmarks of GSCs due to downregulation of Nrf2 expression. Hence, hinokitiol may serve as a promising agent for the therapy of glioma.
KeywordsHinokitiol Glioma stem cells Nrf2 Cancer stemness
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest.
The present study was supported by Grants from the Changhua Christian Hospital and Chung Shan Medical University (CSMU-CCH-103-05) in Taiwan.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 15.Shih YH, Lin DJ, Chang KW, Hsia SM, Ko SY, Lee SY, Hsue SS, Wang TH, Chen YL, Shieh TM (2014) Evaluation physical characteristics and comparison antimicrobial and anti-inflammation potentials of dental root canal sealers containing hinokitiol in vitro. PLoS One 9:e94941CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Huang CH, Jayakumar T, Chang CC, Fong TH, Lu SH, Thomas PA, Choy CS, Sheu JR (2015) Hinokitiol exerts anticancer activity through downregulation of MMPs 9/2 and enhancement of catalase and SOD enzymes. In vivo augmentation of lung histoarchitecture. Molecules 20:17720–17734CrossRefPubMedGoogle Scholar
- 28.Kanamori M, Higa T, Sonoda Y, Murakami S, Dodo M, Kitamura H, Taguchi K, Shibata T, Watanabe M, Suzuki H, Shibahara I, Saito R, Yamashita Y, Kumabe T, Yamamoto M, Motohashi H, Tominaga T (2015) Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients. Neuro-Oncology 17:555–565CrossRefPubMedGoogle Scholar
- 37.Escoll M, Gargini R, Cuadrado A, Anton IM, Wandosell F (2017) Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ. Oncogene (Epub ahead of print)Google Scholar
- 38.Li LH, Wu P, Lee JY, Li PR, Hsieh WY, Ho CC, Ho CL, Chen WJ, Wang CC, Yen MY, Yang SM, Chen HW (2014) Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib-resistant lung adenocarcinoma cells. PLoS One 9:e104203CrossRefPubMedPubMedCentralGoogle Scholar